Status | Study |
Terminated |
Study Name: Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide Condition: Pulmonary Hypertension Date: 2014-06-19 Interventions: Drug: Inhaled Iloprost A 20 mcg dose of Iloprost will be given initially. |
Recruiting |
Study Name: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) Condition: Hypertension, Pulmonary Date: 2014-04-16 Interventions: Drug: Riociguat (ADEMPAS, BAY63-2521) The treatment of Riociguat should comply with the local product in |
Recruiting |
Study Name: EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension Condition: Hypertension, Pulmonary Date: 2014-03-19 Interventions: Drug: Riociguat(BAY63-2521) The decision on clinical management of the patient including the actual trea |
Recruiting |
Study Name: Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension Condition: Hypertension, Pulmonary Date: 2013-09-20 Interventions: Drug: Iloprost (Ventavis, BAYQ6256) |
No longer available |
Study Name: Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Condition: Hypertension, Pulmonary Date: 2013-02-04 Interventions: Drug: Adempas (Riociguat, BAY63-2521) Individual dosing of riociguat between 0.5 and 2.5 mg three times |
Recruiting |
Study Name: Inhaled Nitrite in Subjects With Pulmonary Hypertension Condition: Pulmonary Hypertension Date: 2011-09-06 Interventions: Drug: Inhaled Nitrite Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one pl |
Terminated |
Study Name: A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension Condition: Hypertension, Pulmonary Date: 2009-02-27 Interventions: Drug: PF-00489791 tablet form, |
Active, not recruiting |
Study Name: Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) Condition: Hypertension, Pulmonary Date: 2008-06-09 Interventions: Drug: Riociguat (Adempas, BAY63-2521) BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID |
Completed |
Study Name: Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID Condition: Hypertension, Pulmonary Date: 2008-05-16 Interventions: Drug: Riociguat (Adempas, BAY63-2521) The investigational drug will be given twice per subject, as singl |
Completed |
Study Name: Aerobic Exercise in Patients With Pulmonary Hypertension Condition: Hypertension, Pulmonary Date: 2008-05-14 Interventions: Procedure: Excerise Training Procedure: Pa |